Trial Profile
Phase II Study of an Anti-Epidermal Growth Factor Receptor (EGFR) Antibody, Cetuximab, in Patients With Irinotecan-Refractory, Stage IV Colorectal Carcinoma
Status:
Completed
Phase of Trial:
Phase II
Latest Information Update: 03 Nov 2021
Price :
$35
*
At a glance
- Drugs Cetuximab (Primary)
- Indications Colorectal cancer
- Focus Therapeutic Use
- 10 Sep 2005 New trial record.